anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides multimer alhumin nanospheres. The multimer alhumin nanospheres comprise alhumin molecules containing sulfhydryl groups and/or disulfide bonds. The alhumin molecules are connected through the disulfide bonds; and the particle size of the multimer alhumin nanospheres is 10-1,000 nm. The multimer alhumin nanospheres are safely and stably biocompatible nano vectors, can encapsulate a target delivery object such as a drug or a contrast agent, have high storage stability, and are beneficial to release the target delivery object effectively and stably for a long time. Besides, the multimer alhumin nanospheres have small and uniform particle size, and good dispersibility. The invention also provides a preparation method and an application of the multimer alhumin nanospheres.
The invention relates to the technical field of animal vaccine preparation and discloses a streptococcus suis serotype 2 XD strain and application. The preservation number of the streptococcus suis serotype 2 XD strain is CCTCC NO:M2016573. The streptococcus suis serotype 2 XD strain is the natural attenuated virus bacterial strain, is consistent with most of streptococcus suis serotype 2 epidemic strains in virulence gene phenotype and has the beneficial effects that virulence is not caused to pigs, and immunogenicity is good. Meanwhile, a diluent of the SS2-XD strain is provided, the immunocompetence of the animal bodies can be improved, and generation of streptococcus suis serotype 2 diseases can be more effectively prevented. Through a large number of clinical test evidences, it is shown that the live vaccine plays a positive role on control over the streptococcus suis disease and has the beneficial effects of early prevention, mucosal immune and cellular immunity induction and the like. Obvious advantages are achieved for prevention of the streptococcus suis disease frequently happening clinically.
Parenteral nutrition (PN) therapy is an essential component of medical management of patients suffering from intestinal failure. Depending on the underlying etiology and the type of intestinal failure, the duration of parenteral nutrition therapy could range from several weeks to several years, although a substantial proportion of these patients also require lifelong parenteral nutrition support. These patients continue the infusion of PN at their homes and are managed by the Cleveland Clinic's Home PN support team. These patients require Central Venous Catheters (CVC) for prolonged period of time for infusion of parenteral nutrition. The two most commonly used central catheters for TPN infusion are the Peripherally Inserted Central Catheter (PICC) and Tunneled CVCs. Catheter related blood stream infection (CRBSI) is a major complication of long-term CVCs. CRBSI is associated with high morbidity, mortality and healthcare cost. Additionally, CRBSI can also lead to an interruption in nutrient delivery, loss of work and productivity, premature vascular access device removal, and poor quality of life.

Prevention of CRBSI is an important component of clinical management of patients receiving home PN therapy. Several strategies have been adopted to reduce the incidence of CRBSI. A heparin lock solution was used in the past for many years; however, current nutrition society guidelines recommend normal saline locks instead of heparin locks. Published data has suggested that heparin locks have not proven to have a substantial effect on CRBSI prevention, and it paradoxically increases the infection risk due to biofilm production. Antibiotic locks have also been used, although this practice is largely not preferred due to increased risk of infections with resistant microorganisms. Taurolidine is another lock solution which has been studied in the countries outside the United States such as Canada; however, it has not been approved for the use in the U.S. yet.1
OBJECTIVES: The aims of this study were to (1) establish the maximum allowable interference limits for hemolysis, lipemia, and icterus for chemistry analytes tested in body fluid samples and (2) assess the effectiveness of serial dilution to mitigate spectral interferences.
METHODS: Residual body fluids from clinically ordered testing were mixed (<10% by volume) with stock solutions of interferent (spiked) and compared with a control spiked with an equal volume of 0.9% saline. The analytes were measured on the Roche cobas c501 instrument. Difference and percentage difference were calculated and compared with allowable total error limits. A subset of samples were serially diluted with 0.9% saline. Mean (SD) difference and percentage difference were calculated.
RESULTS: The interference thresholds were lower than the package insert for lactate dehydrogenase, cholesterol, triglycerides, and total protein for hemolysis; amylase, cholesterol, and total protein for icterus; and albumin for lipemia. Only cholesterol and triglyceride results returned to baseline upon dilution of icteric samples.
CONCLUSIONS: Interference thresholds in body fluids were lower than blood for 6 analytes. Diluting interferences that surpass these limits does not produce reliable results that are comparable to the baseline results before spiking in the interferent.
Thrombotic microangiopathy (TMA) is characterized by immunothrombosis and life-threatening organ failure but the precise underlying mechanism driving its pathogenesis remains elusive. In this study, we hypothesized that gasdermin D (GSDMD), a pore-forming protein that serves as the final downstream effector of the pyroptosis/interleukin-1β (IL-1β) pathway, contributes to TMA and its consequences by amplifying neutrophil maturation and subsequent necrosis. Using a murine model of focal crystalline TMA, we found that Gsdmd deficiency ameliorated immunothrombosis, acute tissue injury, and failure. Gsdmd-/- mice exhibited a decrease in mature IL-1β, as well as in neutrophil maturation, β2-integrin activation, and recruitment to TMA lesions, in which they formed reduced neutrophil extracellular traps in both arteries and interstitial tissue. The GSDMD inhibitor disulfiram dose-dependently suppressed human neutrophil pyroptosis in response to cholesterol crystals. Experiments with GSDMD-deficient, human-induced, pluripotent stem cell-derived neutrophils confirmed the involvement of GSDMD in neutrophil β2-integrin activation, maturation, and pyroptosis. Both prophylactic and therapeutic administration of disulfiram protected the mice from focal TMA, acute tissue injury, and failure. Our data identified GSDMD as a key mediator of focal crystalline TMA and its consequences, including ischemic tissue infarction and organ failure. GSDMD could potentially serve as a therapeutic target for the systemic forms of TMA.
Patients receive paclitaxel infusion QD and receive cryocompression therapy with cooling compression wraps TID over 15 minutes before, during, and after receiving paclitaxel infusion on day 1 of each cycle. Patients also receive cilostazol PO BID beginning with their first paclitaxel infusion continuing until 2 weeks after the final paclitaxel infusion. Treatment with paclitaxel continues for up to 6-9 cycles in the absence of disease progression or unacceptable toxicity.
While varenicline on its own is the most effective medication for smoking cessation, long-term abstinence is still relatively poor. The primary objective of this study is to evaluate the effectiveness of adjunct active tDCS with varenicline in treating tobacco dependence. This study is a double-blind, sham-controlled, randomized clinical trial where 50 daily dependent treatment seeking smokers will be recruited at the Nicotine Dependence Clinic in Toronto, Canada. Participants will be receiving twelve weeks of varenicline treatment (1mg b.i.d.) and randomized 1:1 to either active tDCS (active: 20 minutes at 2 mA) or sham tDCS (30 seconds at 2 mA, 19.5 minutes at 0 mA), daily (M-F) for the first 2 weeks and then every 2 weeks for the next 10 weeks. There will be 2 fMRI scans at baseline and 1 scan at end-of-treatment. Eye-tracking viewing tests will be conducted at baseline, weeks 4, 8, 12 and at 6 months follow up. During the 6 month follow-up, participants will be answering questions regarding their smoking behaviour and craving. Smoking status will be biochemically confirmed at each study visit using expired cotinine.
The invention discloses ferulic microcapsule floating tablets. The tablets comprise microcapsules with a capsule core material of ferulic volatile oil, dry extract with a main component of a ferulic water-soluble component, pharmacologically acceptably auxiliary materials, and magnesium stearate. The microcapsules accounts for 3-15% of the ferulic microcapsule floating tablets by weight. The ferulic water-soluble dry extract accounts for 3-15% of the ferulic microcapsule floating tablets by weight. The balance is the pharmacologically acceptably auxiliary materials. The invention also discloses a preparation method of the ferulic microcapsule floating tablets. Compared with prior arts, with the ferulic microcapsule floating tablets and the method, ferulic overall utilization rate is high, ferulic volatile oil component is well preserved, and ferulic odor can be effectively covered.
The procedures were performed at outpatient clinic without anesthesia. Lyophilized 100 IU BT Type-A (BOTOX, Alergan, CA, USA) was applied after diluted with 1 cc saline. A 26-G injector was used to inject 25 unit toxin in every 4 quadrants, to the alignment of clock 12, 3, 6, and 9 to internal anal sphincters. After BT injection, topical 2% diltiazem gel was prescribed, applied 2 times per day for 10 days (2 doses of 1 gr each per day). No selection criteria were used when recommending this treatment; it was randomly suggested to some for a while during the cohort since the surgeon believed it might enhance the efficacy of BT.
A method includes determining team participant members for one or more wellness teams. The method includes aggregating participant medical data for each of the one or more wellness teams from one or more networked physiologic stations configured to receive the medical data. The method includes analyzing the medical data to determine wellness information for the one or more wellness teams associated with the aggregated participant medical data. The method can be operated on a system where the system includes at least one physiologic station to generate participant medical information from a plurality of participants. This can include an identification component to facilitate trust in collected data. A storage medium collects the medical information over a network from the plurality of participants and an analyzer determines group wellness information from the collected medical information.
* Prescribe HYCODAN for the shortest duration that is consistent with individual patient treatment goals [see Warnings and Precautions (5.1)].
  * Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy [see Warnings and Precautions (5.2)].
  * Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease [see Warnings and Precautions (5.4)]. If a patient requires a refill, reevaluate the cause of the cough and assess the need for continued treatment with HYCODAN, the relative incidence of adverse reactions, and the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1)].
  * Do not abruptly discontinue HYCODAN in a physically-dependent patient [see Drug Abuse and Dependence (9.3)]. When a patient who has been taking HYCODAN regularly and may be physically dependent no longer requires therapy with HYCODAN, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both.
PURPOSE: Provided are double-coated cosmetic containing the first and second compositions, uses thereof and a makeup kit containing the same. The cosmetic has long lasting make-up activity, gives even skin tone and covers up blemishes. CONSTITUTION: The double-coated cosmetic is characterized by containing the first and second compositions, wherein the first composition contains the first physiologically acceptable substrate and has a haze index of 40% and a transparency index of 70% and the second composition contains the second physiologically acceptable substrate. The make-up kit contains the double-coated cosmetic. The first and second compositions compose a basecoat and a topcoat, respectively. The first composition is selected from fillers, organic siloxane and low molecular weight of non-silicon containing polymers.
Adjuvant therapy after surgery for breast cancer has provided significant benefits to patients at risk for relapse. However, the success of therapy for each individual patient will often take years to reveal. Preoperative (neoadjuvant) medical therapy is very potent as an initial treatment for inoperable and large operable breast cancers. Tumor regression can be achieved in the great majority of patients and downstaging frequently reduces the need for mastectomy and it has become clear that pathologic complete response is a good prognostic marker. Data from current trials suggest that survival is at least as good with preoperative as with postoperative neoadjuvant therapies (1). With this observation preoperative medical therapy has the advantage over post-operative neoadjuvant therapy that it can be used as a short term surrogate marker for long-term outcome. With this translational approach, the therapy for each patient can be more targeted and individualized leading to higher success rates; and further, new therapies for early breast cancer can be assessed much more quickly than is currently possible through protracted trials of neoadjuvant therapy (2). This approach is therefore being increasingly utilized in patients with lower stage breast cancers.
<P>PROBLEM TO BE SOLVED: To provide a composition containing a new protein and the use of the same for the diagnosis and treatment of immune-related diseases.  <P>SOLUTION: This PRO polypeptide based on the identification of a protein obtained as a result of stimulating the immunological responses of a mammalian animal is provided. Also, a method for identifying the agonist of the PRO polypeptide or the antagonist of the PRO polypeptide is provided. A medicine and a medical agent containing the therapeutically effective amount of the PRO polypeptide having a pharmaceutically acceptable carrier and its agonist or antagonist are provided. And an anti-PRO antibody is also provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention relates to a universal mobile interactive information equipment that is used, in particular, to monitor a dependent elderly person.  The inventive piece of equipment is characterised in that it comprises an autonomous portable unit which can operate independently of all other communication and connection means and which can also be connected to said means.  The aforementioned portable unit comprises a carrying case containing a portable computer which manages an information system and which contains different software programs.  Access to the computer is authorised with a triple chip card reader comprising a reader for the dependent elderly person's (P.A.D.) personal card, called the patient card, a reader for the  Sesame Vitale  card and a reader for the professional health care card (C.P.S) of a person identified as a health care professional or any related card.  A numeric keypad is used to enter information and control the program(s).
The invention provides a shoe pad for improving sleep. The shoe pad sequentially comprises a bottom layer, a middle layer and a fabric layer from bottom to top. The middle layer is made of a fabric treated by using a treating fluid for improving sleep. The treating fluid for improving sleep is prepared from, by weight, 8-12 parts of tuber fleece-flower stems, 4-6 parts of radix aucklandiae, 4-6 parts of tribulus terrestris, 2-4 parts of ginkgo leaves, 4-6 parts of phoenix tree seed, 2-4 parts of longan, 1-3 parts of an umbellate rockjasmine herb, 1-3 parts of a diverse wormwood herb and 4-6 parts of rose. The fabric layer is formed by weaving warp yarns and weft yarns and provided with mesh holes, the warp yarns are antibacterial fibers containing silver nanoparticles, the weft yarns are fibers treated by using a treating fluid for promoting absorption, and the treating fluid for promoting absorption is at least prepared from, by weight, 10-20 parts of cinnamon, 4-6 parts of white hyacinth beans, 2-4 parts of bezoar, 2-4 parts of folium eucalypti and 1-3 parts of Chinese rose. The shoe pad raw materials are common, and the shoe pad is convenient to use through plantar absorption and has a remarkable sleep improving effect.
This article is the third in a series of eight articles that comprise this special issue on family-centered early intervention for children who are deaf or hard of hearing and their families (FCEI-DHH). It highlights the origins of FCEI-DHH in Western contexts and well-resourced locations and emphasizes the role of culture(s) in shaping FCEI-DHH. This article also cautions against the direct application of the 10 FCEI-DHH Principles presented in this issue across the globe without consideration of cultural implications. Cultural perceptions of decision-making processes and persons who can be decision-makers in FCEI-DHH are explored. Deaf culture(s) and the benefits of exposure to DHH adults with diverse backgrounds are introduced. Structural inequities that impact families' access to FCEI-DHH programs/services and systems, within and among nations and regions, are noted. The need to consider the cultural influences on families is emphasized; this applies to all levels of FCEI, including the development of systems through implementation of supports.
This study aims to explore the potential inhibition effects of staurosporine isolated from a Streptomyces sp. SNC087 strain obtained from seawater on nasal polyps. Staurosporine possesses antimicrobial and antihypertensive activities. This research focuses on investigating the effects of staurosporine on suppressing the growth and development of nasal polyps and elucidating the underlying mechanisms involved. The experimental design includes in vitro and ex vivo evaluations to assess the inhibition activity and therapeutic potential of staurosporine against nasal polyps. Nasal polyp-derived fibroblasts (NPDFs) were stimulated with TGF-β1 in the presence of staurosporine. The levels of α-smooth muscle actin (α-SMA), collagen type-I (Col-1), fibronectin, and phosphorylated (p)-Smad 2 were investigated using Western blotting. VEGF expression levels were analyzed in nasal polyp organ cultures treated with staurosporine. TGF-β1 stimulated the production of Col-1, fibronectin, and α-SMA and was attenuated by staurosporine pretreatment. Furthermore, these inhibitory effects were mediated by modulation of the signaling pathway of Smad 2 in TGF-β1-induced NPDFs. Staurosporine also inhibits the production of VEGF in ex vivo NP tissues. The findings from this study will contribute to a better understanding of staurosporine's role in nasal polyp management and provide insights into its mechanisms of action.
OBJECTIVES: We sought to compare the latest data on postoperative pain between robot-assisted thoracic surgery (RATS) and video-assisted thoracoscopic surgery (VATS), and to clarify the relationship between the number or placement of ports and postoperative pain in patients with lung cancer.
METHODS: Patients who underwent anatomical lung resection by RATS or VATS and whose chest tube was removed within 7 days were enrolled. The primary endpoint was the percentage of patients with a numeric rating scale (NRS) score ≤ 3 on postoperative day 30 (POD30). The target sample size was 400 patients.
RESULTS: Four hundred five patients (RATS, n = 196; VATS, n = 209) managed at 12 institutions were included. Ninety-nine patients in the VATS group underwent a uniport procedure. Significant differences were observed between the RATS and VATS groups in the mean number of inserted ports (5.0 vs. 2.2), number of injured intercostal sites (2.9 vs. 1.9), largest wound size (3.4 vs. 3.7 cm), operation time (202 vs. 165 min), and use of epidural anesthesia or continuous nerve block (45 vs. 31 %). In the RATS and VATS groups, the rates of NRS≤3 on POD30 were 82.0 % and 94.7 % (95 %CI: -19.0 to -6.6 %), respectively, which could not prove noninferiority. However, in a multivariable analysis, the RATS approach was not proven to be a significant risk factor.
CONCLUSION: In the current status of minimally invasive thoracic surgery in Japan, RATS involves a greater number of ports, longer operation time, and higher frequency of local anesthesia than VATS and may be inferior in terms of postoperative pain.
This 6-week program includes orientation session, six 2-hour sessions, held weekly. Parents will be provided with information on existing services in the region, and strategies to be strong advocates and plan and access services for their child. Each session will include a presentation by an expert, with a question answer period, a break, and facilitated discussion with other parents. The sessions will be co-facilitated by clinicians from the Disability Services Ontario (DSO) and Centre for Addiction and Mental Health (CAMH).
The control group will receive a "usual care" educational programme at baseline created by the Singapore Health Promotion Board. This guide describes the importance of physical activity and illustrates one possible physical activity programme. It also discusses strategies for adopting a healthy lifestyle. They will not receive the Fitbit Zip wireless pedometer from the study team. However, they will receive $4 per week, regardless of physical activity levels.
Patients receive docetaxel IV over 30 minutes followed 4-6 hours later by flavopiridol IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
INTRODUCTION: Cardiac blood cyst is a very rare benign tumor of the heart in adults. Though it is very common in the first half year of life, it regresses with time and its occurrence is very rare in children older than six months and in adults. Until now less than 100 valvular blood cyst cases have been reported in adults.
CASE PRESENTATION: We present a case of a 66-year-old male who presented to us with exertional chest tightness, shortness of breath, and right leg weakness for two weeks. He was diagnosed with a cardiac mass two months ago in another hospital. The physical examination was unremarkable. Abdominal ultrasound showed a cyst in the liver and left kidney. Echocardiography showed a mass-occupying lesion of a cystic nature in the mitral valve with moderate mitral regurgitation. Based on echocardiography findings and computed tomography report, the preliminary diagnosis of mitral valve cystic tumor was made. The patient underwent minimally invasive resection of the cyst. The posterior mitral cusp was repaired and a mitral annuloplasty ring was placed. The postoperative recovery was uneventful. The histopathology report confirmed the diagnosis of a cardiac blood cyst. The patient was followed up for six months without any complications. This case is presented to enrich the medical literature on the cardiac blood cyst.
CONCLUSION: Although a cardiac blood cyst is a rare entity in adults, it still should be considered in the differential diagnosis of cardiac tumors. Because the natural history and hemodynamic effects are very diverse, large symptomatic cardiac blood cysts, especially in the left heart should be resected to avoid complications.